Pancreatic cancer: Advances and challenges

Christopher J Halbrook; Costas A Lyssiotis; Marina Pasca di Magliano; Anirban Maitra

doi:10.1016/j.cell.2023.02.014

Pancreatic cancer: Advances and challenges

Cell. 2023 Apr 13;186(8):1729-1754. doi: 10.1016/j.cell.2023.02.014.

Authors

Christopher J Halbrook¹, Costas A Lyssiotis², Marina Pasca di Magliano³, Anirban Maitra⁴

Affiliations

¹ Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92697, USA; Institute for Immunology, University of California, Irvine, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA. Electronic address: chris.halbrook@uci.edu.
² Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: costas.lyssiotis@umich.edu.
³ Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA; Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: marinapa@umich.edu.
⁴ Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: amaitra@mdanderson.org.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant efforts have largely defined major genetic factors driving PDAC pathogenesis and progression. Pancreatic tumors are characterized by a complex microenvironment that orchestrates metabolic alterations and supports a milieu of interactions among various cell types within this niche. In this review, we highlight the foundational studies that have driven our understanding of these processes. We further discuss the recent technological advances that continue to expand our understanding of PDAC complexity. We posit that the clinical translation of these research endeavors will enhance the currently dismal survival rate of this recalcitrant disease.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Pancreatic Ductal* / diagnosis
Carcinoma, Pancreatic Ductal* / drug therapy
Carcinoma, Pancreatic Ductal* / pathology
Carcinoma, Pancreatic Ductal* / surgery
Early Diagnosis
Humans
Pancreatic Neoplasms* / diagnosis
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / pathology
Pancreatic Neoplasms* / surgery
Prognosis
Tumor Microenvironment

Abstract

Publication types

MeSH terms

Grants and funding